Human CAPN5 ELISA Kit (V2LY-0626-LY5544)

See all CAPN5 antibodies
Go to compare Compare Online Inquiry
Tested Data
Datasheet
SDS
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Sensitivity
0.0091 ng/mL
Detection Range
0.02-4.5 ng/mL
Sample Type
Serum, Plasma, cell culture supernates
Specificity
Human
Assay Type
Sandwich
Reactivity
Human
Assay Time
1.5 h
Molecule Mass
73.2 kDa
Components
  • Pre-coated ELISA plate: 12 wells * 8 detachable strips
  • Standard solution: 0.5ml x1
  • Standard diluent: 3ml x1
  • Streptavidin-HRP: 6ml x1
  • Stop solution: 6ml x1
  • Substrate solution A: 6ml x1
  • Substrate solution B: 6ml x1
  • Wash buffer concentrate (25x): 20ml x1
  • Biotinylated antibody: 1ml x1

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 2-8°C
More Infomation

Target

Full Name
Calpain 5
Function
Calcium-regulated non-lysosomal thiol-protease.
Biological Process
Proteolysis Source: GO_Central
Signal transduction Source: ProtInc
Cellular Location
Extracellular exosome; Cell surface; Cytoplasm; Focal adhesion
Involvement in disease
Vitreoretinopathy, neovascular inflammatory (VRNI): An autoimmune condition of the eye that sequentially mimics uveitis, retinitis pigmentosa, and proliferative diabetic retinopathy as it progresses to complete blindness. Patients present during the second or third decade of life with posterior uveitis and reduction of the electroretinogram b-wave. They become more symptomatic when cataracts, cystoid macular edema, and disk edema diminish visual acuity during the second stage. Severe vision loss begins during the third stage when proliferative retinal neovascularization and epiretinal membranes appear. There is an ongoing pigmentary retinal degeneration and peripheral visual field loss during all stages. In the fourth stage, proliferative vitreoretinopathy causes tractional retinal detachments at the macula and vitreous base. The fifth or end-stage disease is marked by phthisis.

Bondada, V., Gal, J., Mashburn, C., Rodgers, D. W., Larochelle, K. E., Croall, D. E., & Geddes, J. W. (2021). The C2 domain of calpain 5 contributes to enzyme activation and membrane localization. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1868(7), 119019.

Tang, P. H., Chemudupati, T., Wert, K. J., Folk, J. C., Mahajan, M., Tsang, S. H., ... & Mahajan, V. B. (2020). Phenotypic variance in Calpain-5 retinal degeneration. American journal of ophthalmology case reports, 18, 100627.

Wert, K. J., Koch, S. F., Velez, G., Hsu, C. W., Mahajan, M., Bassuk, A. G., ... & Mahajan, V. B. (2019). CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials. Human mutation, 40(12), 2377-2392.

Randazzo, N. M., Shanks, M. E., Clouston, P., & MacLaren, R. E. (2019). Two novel CAPN5 variants associated with mild and severe autosomal dominant neovascular inflammatory vitreoretinopathy phenotypes. Ocular immunology and inflammation, 27(5), 693-698.

Coomer, C. E., & Morris, A. C. (2018). Capn5 expression in the healthy and regenerating zebrafish retina. Investigative ophthalmology & visual science, 59(8), 3643-3654.

Velez, G., Bassuk, A. G., Schaefer, K. A., Brooks, B., Gakhar, L., Mahajan, M., ... & Mahajan, V. B. (2018). A novel de novo CAPN5 mutation in a patient with inflammatory vitreoretinopathy, hearing loss, and developmental delay. Molecular Case Studies, 4(3), a002519.

Bruening, J., Lasswitz, L., Banse, P., Kahl, S., Marinach, C., Vondran, F. W., ... & Gerold, G. (2018). Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. PLoS pathogens, 14(7), e1007111.

Schaefer, K., Mahajan, M., Gore, A., Tsang, S. H., Bassuk, A. G., & Mahajan, V. B. (2017). Calpain-5 gene expression in the mouse eye and brain. BMC research notes, 10(1), 1-7.

Wang, Y., Zhang, X., Song, Z., & Gu, F. (2017). An anti-CAPN5 intracellular antibody acts as an inhibitor of CAPN5-mediated neuronal degeneration. Oncotarget, 8(59), 100312.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Human CAPN5 ELISA Kit?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-CAPN5 Recombinant Antibody (3C10) (CAT#: CBMAB-C5774-LY)

Mouse Anti-CAPN5 Recombinant Antibody (CBFYC-0798) (CAT#: CBMAB-C0853-FY)

Mouse Anti-CAPN5 Recombinant Antibody (7F2) (CAT#: CBMAB-C8694-LY)

Rabbit Anti-CAPN5 Recombinant Antibody (CBXC-3044) (CAT#: CBMAB-C3681-CQ)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry
Request bulk or custom quote Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.